The MYL1 antibody targets myosin light chain 1 (MYL1), a protein encoded by the MYL1 gene, which belongs to the myosin light chain family. MYL1 is a regulatory component of myosin, a motor protein critical for muscle contraction and cellular motility. Specifically, MYL1 is expressed in skeletal muscle and cardiac tissue, where it plays a role in calcium-dependent regulation of actomyosin ATPase activity, influencing the contractile properties of muscle fibers.
MYL1 antibodies are widely used in research to study muscle development, differentiation, and function. They are employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect MYL1 expression levels and localization in tissues or cell lines. Aberrant MYL1 expression has been implicated in certain pathological conditions, including muscular dystrophies, cardiomyopathies, and cancers such as rhabdomyosarcoma. In cancer biology, MYL1 overexpression is linked to enhanced cell migration and invasion, suggesting its potential as a biomarker for tumor aggressiveness.
Recent studies also explore MYL1's role in non-muscle cells, particularly in cytoskeletal reorganization during processes like cytokinesis and cell adhesion. Species cross-reactivity of MYL1 antibodies (e.g., human, mouse, rat) makes them versatile tools in comparative physiology and translational research. Ongoing investigations aim to clarify MYL1's post-translational modifications (e.g., phosphorylation) and its interactions with other myosin subunits, which could inform therapeutic strategies for muscle-related disorders or metastatic cancers.